Q2 FY2026 · ended Jun 30, 2026 · Revenue $17.87M, +85.2% YoY · Filed Aug 13, 2026
Fennec Pharmaceuticals Inc. (FENC) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $17.9 million and net income of $2.0 million.
Revenue
$17.87M
+85.2% vs year-ago quarter
Net income
$1.97M
+162.6% vs year-ago quarter
Operating cash flow
$50,000
+101.4% vs year-ago quarter
Free cash flow
—
EPS
$0.05
+145.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
35.07M
+26.0% vs year-ago quarter
Net cash
$2.57M
Q3 FY2025
Operating margin
-1.9%
TTM
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FENC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Research Triangle Park, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1211583
- Former names
- ADHEREX TECHNOLOGIES INC (until Aug 14, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $17.9M | $15.1M | $13.8M | $12.5M | $9.7M |
| Operating income | $1.7M | -$119,000 | -$2.6M | -$189,000 | -$2.7M |
| Net income | $2.0M | $201,000 | -$4.8M | -$638,000 | -$3.2M |
| Diluted EPS | $0.05 | $0.01 | -$0.15 | -$0.02 | -$0.11 |
| Operating cash flow | $50,000 | $2.4M | -$6.0M | $1.5M | -$3.7M |
| Total assets | $75.8M | $71.8M | $70.6M | $49.3M | $44.9M |
| Total liabilities | $33.3M | $34.1M | $35.1M | $53.8M | $52.3M |
| Stockholders' equity | $42.4M | $37.7M | $35.5M | -$4.5M | -$7.5M |
| Cash and investments | $41.2M | $40.2M | $36.8M | $21.9M | $18.7M |
| Total debt | — | — | — | $19.4M | $19.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 17, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Other events
|
May 22, 2026 | May 21, 2026 |
| 8-K |
Current report
Officer or director change
|
May 18, 2026 | May 18, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 853 Fennec Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.